The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma

Annals of Hematology

Volumn 80, Issue 1, 2001, Pages 2-8

  Nieder, C ^a   Petersen, S ^a   Petersen, C ^a   Thames, H D ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hodgkin's lymphoma; Lymphoma; Non Hodgkin's lymphoma; p53; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; CANCER ANTIBODY; DNA; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; HYPOTHESIS; INFORMATION PROCESSING; LYMPHATIC SYSTEM DISEASE; MEDICAL LITERATURE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

DISEASE-FREE SURVIVAL; GENES, P53; HODGKIN DISEASE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, DIFFUSE; LYMPHOMA, NON-HODGKIN; MUTATION; PROGNOSIS; SURVIVAL RATE;

EID: 0035138599     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770000226     Document Type: Review

References (35)

1. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress
2. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: Involvement of apoptosis resistance?
3. Primary central nervous system lymphomas in 72 immunocompetent patients: Pathologic findings and clinical correlations
4. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases
5. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis
6. Prognostic significance of p53 mutations in small non-cleaved cell lymphomas
7. p53 protein expression in gastrointestinal lymphomas
8. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades
9. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas
10. Lymphoma classification - The gap between biology and clinical management is closing
11. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
12. Tumor suppressor p53: Implications for tumor development and prognosis
13. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma
14. Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: A multivariate survival analysis including Ki67 and p53
15. Prognostic implications of proliferating cell nuclear antigen, AgNORs and p53 in non-Hodgkin's lymphomas
16. Clinical significance of bc12 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study
17. Primary central nervous system lymphomas in immunocompetent individuals: Histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression
18. p53 overexpression as a matter of poor prognosis in mantle cell lymphomas with t(11;14) (q13;q32)
19. Genetic abnormalities in non-Hogdkin's lymphomas and chronic lymphocytic leukemia
20. Structures and functions of the tumor suppressor p53
21. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma
22. Aberrations of the p53 pathway components p53, MDM2, and CDKN2A appear independent in diffuse large B-cell lymphoma
23. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression
24. Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma
25. Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas
26. p53 gene mutations in lymphoid diseases and their possible relevance to drug resistance
27. p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time
28. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases
29. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
30. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins
31. p53 mutation is associated with progression in follicular lymphomas
32. Expression of proliferating cell nuclear antigen and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: Prognostic significance in Hodgkin's disease
33. The p53 tumour suppressor gene
34. MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma
35. Expression of the p53 gene in Hodgkin's disease: Dissociation between immunohistochemistry and clinicopathological data